Therapeutic targeting of alternative pathway and C5 but not C5a protects from disease development in a preclinical model of autoimmune blistering dermatosis
Our findings identify combined C5/AP targeting as a novel therapeutic option for autoimmune blistering dermatoses.
Authors
- Björn Laffer (ORCID: https://orcid.org/0000-0001-5060-8127)
- Elvira Ehlers-Jeske
- Samyr Kenno (ORCID: https://orcid.org/0000-0002-9448-7344)
- Wenru Song
- Ping Tsui
- Mareike Ohms
- Wen‐Chao Song (ORCID: https://orcid.org/0009-0004-1740-843X)
- Jörg Köhl
Institutions
- AVEO Oncology (United States) (US)
- Translational Therapeutics (United States) (US)
- University of Pennsylvania (US)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1560468
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft